In conclusion, understanding the mechanisms involving AKR1C3 in endocrine therapy resistance, particularly in prostate and breast cancers, is critical for developing targeted therapies that can overcome drug resistance and improve treatment outcomes. Here, AKR1C3 is linked to breast carcinoma.